Press Releases

Date Title and Summary View
Toggle Summary Revance Therapeutics Announces Closing of Its Follow-on Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
Gross Proceeds of Offering Total $140.3 Million
View HTML
Toggle Summary Revance Therapeutics Announces Pricing of Its Public Offering of Common Stock
NEWARK, Calif. , June 18, 2014 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (Nasdaq:RVNC) today announced the pricing of its underwritten public offering of 4,000,000 shares of its common stock at a price to the public of $30.50 per share pursuant to a registration statement filed with the
View HTML
Toggle Summary Revance Therapeutics Announces Proposed Public Offering of Common Stock
NEWARK, Calif. , June 16, 2014 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (Nasdaq:RVNC) today announced a proposed underwritten public offering of 3,000,000 shares of its common stock pursuant to a registration statement filed with the Securities and Exchange Commission (SEC).
View HTML
Toggle Summary Revance Therapeutics Clinical Data to be Presented in "Emerging Technologies" Panel at the International Symposium of Facial Plastic Surgery in New York City
NEWARK, Calif. , May 21, 2014 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (Nasdaq:RVNC), announced that the company's proprietary, botulinum toxin (BoNTA) investigational products will be the lead topics discussed in the Emerging Technologies panel at the 11th International Symposium of Facial
View HTML
Toggle Summary Revance Therapeutics, Inc. Announces Participation in Jefferies 2014 Global Healthcare Conference
NEWARK, Calif., May 21, 2014 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (Nasdaq:RVNC), today announced that its management is scheduled to participate in the Jefferies 2014 Global Healthcare Conference in New York. Revance management is scheduled to present on Monday, June 2, 2014 at 8:00 am
View HTML
Toggle Summary Revance Therapeutics Releases First Quarter 2014 Financial Results
Reiterates Full-Year Financial Guidance
View HTML
Toggle Summary Revance Appoints Mark A. Prygocki to Its Board of Directors
NEWARK, Calif., May 12, 2014 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (Nasdaq:RVNC), a specialty biopharmaceutical company that develops botulinum toxin products for use in aesthetic and therapeutic indications, today announced that Mark A. Prygocki has been appointed to its Board of
View HTML
Toggle Summary Revance Therapeutics to Release First Quarter 2014 Financial Results and Host Conference Call on Tuesday, May 13, 2014
NEWARK, Calif. , April 29, 2014 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (Nasdaq:RVNC), a specialty biopharmaceutical company which develops botulinum toxin products for use in aesthetic and therapeutic indications, today announced that the company will release first quarter 2014 financial
View HTML
Toggle Summary Revance Therapeutics Announces Positive Results From the RT002 Phase 1/2 Study in Glabellar Frown Lines
Median Duration of 7.3 Months
View HTML
Toggle Summary Revance Therapeutics Added to Russell 2000(R) and 3000(R) Indexes
NEWARK, Calif., March 31, 2014 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (Nasdaq:RVNC), today announced the company was added to the Russell 2000® and Russell 3000® Indexes following the reconstitution of Russell Investment Group's family of U.S. indexes after market close on March 31, 2014.
View HTML
Shareholder Tools Request Printed Materials Request Email Alerts Download Library RSS News Feeds Share this Page Search Investor Site
Shareholder Tools